X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4678) 4678
Publication (486) 486
Book Review (49) 49
Book Chapter (41) 41
Dissertation (13) 13
Conference Proceeding (3) 3
Web Resource (2) 2
Data Set (1) 1
Magazine Article (1) 1
Paper (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3010) 3010
index medicus (2502) 2502
pegylated interferon (2436) 2436
antiviral agents - therapeutic use (1845) 1845
ribavirin (1835) 1835
gastroenterology & hepatology (1624) 1624
hepatitis c (1617) 1617
male (1608) 1608
female (1533) 1533
hepatitis c, chronic - drug therapy (1502) 1502
middle aged (1359) 1359
hepatitis c virus (1300) 1300
adult (1245) 1245
interferon (1213) 1213
treatment outcome (1187) 1187
interferon-alpha - therapeutic use (1171) 1171
ribavirin - therapeutic use (1027) 1027
drug therapy, combination (1024) 1024
genotype (884) 884
hepacivirus - genetics (880) 880
polyethylene glycols - therapeutic use (817) 817
therapy (772) 772
sustained virological response (764) 764
pegylated interferon-alpha-2b (750) 750
virus-infection (733) 733
recombinant proteins (723) 723
plus ribavirin (702) 702
biological response modifiers (680) 680
aged (655) 655
hepatitis c - drug therapy (654) 654
hepatitis (649) 649
infectious diseases (645) 645
antiviral agents - adverse effects (621) 621
chronic hepatitis c (591) 591
antiviral agents - administration & dosage (588) 588
virology (579) 579
infection (563) 563
combination therapy (556) 556
health aspects (551) 551
hepacivirus - drug effects (542) 542
peginterferon alpha-2a (542) 542
hepatitis c, chronic - virology (527) 527
care and treatment (515) 515
pharmacology & pharmacy (510) 510
interferon-alpha - administration & dosage (490) 490
hcv (482) 482
viral load (472) 472
ribavirin - administration & dosage (440) 440
antiviral therapy (436) 436
interferon-alpha - adverse effects (434) 434
virus diseases (431) 431
recombinant proteins - therapeutic use (420) 420
antiviral agents (418) 418
chronic hepatitis-c (397) 397
analysis (388) 388
drug therapy (381) 381
liver (371) 371
polyethylene glycols - administration & dosage (368) 368
hepatitis c, chronic - complications (364) 364
cirrhosis (363) 363
gastroenterology and hepatology (348) 348
hepatocellular-carcinoma (345) 345
ribavirin - adverse effects (342) 342
immunology (340) 340
rna, viral - blood (337) 337
pegylated interferon-alpha (327) 327
hiv (326) 326
telaprevir (324) 324
genetic aspects (323) 323
risk factors (321) 321
treatment-naive patients (307) 307
retrospective studies (303) 303
virological response (301) 301
peginterferon (300) 300
efficacy (297) 297
pegylated-interferon (295) 295
virus (295) 295
young adult (293) 293
polyethylene glycols - adverse effects (288) 288
combination (287) 287
medicine, general & internal (284) 284
time factors (276) 276
hepatology (266) 266
transplantation (266) 266
peginterferon alpha-2b (265) 265
recurrence (265) 265
liver transplantation (260) 260
digestive system diseases (259) 259
hiv infections - complications (258) 258
interferon-alpha-2b plus ribavirin (258) 258
hepatitis b (254) 254
initial treatment (254) 254
infections (253) 253
research (247) 247
interleukins - genetics (246) 246
hepatitis b, chronic - drug therapy (245) 245
hepatitis c, chronic - genetics (244) 244
genotype 1 infection (239) 239
prospective studies (236) 236
interferons - therapeutic use (235) 235
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4328) 4328
Korean (83) 83
Spanish (66) 66
French (51) 51
Japanese (45) 45
German (41) 41
Hungarian (35) 35
Czech (22) 22
Polish (18) 18
Russian (15) 15
Turkish (11) 11
Portuguese (10) 10
Chinese (8) 8
Serbian (4) 4
Slovak (4) 4
Croatian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


GASTROENTEROLOGY, ISSN 0016-5085, 01/2016, Volume 150, Issue 1, pp. 134 - 134
BACKGROUND & AIMS: Patients chronically infected with the hepatitis B virus rarely achieve loss of serum hepatitis B surface antigen (HBsAg) with the standard... 
Virologic Response | ENTECAVIR | PEGYLATED INTERFERON ALPHA-2A | CONTROLLED TRIAL | VIRUS | Clinical Trial | ADEFOVIR | HBSAG | NATURAL-HISTORY | LAMIVUDINE | HBeAg Seroconversion | THERAPY | TERM-FOLLOW-UP | GASTROENTEROLOGY & HEPATOLOGY | HBV
Journal Article
Journal of Hepatology, ISSN 0168-8278, 11/2018, Volume 69, Issue 5, pp. 1204 - 1205
Journal Article
LANCET ONCOLOGY, ISSN 1470-2045, 04/2018, Volume 19, Issue 4, pp. 510 - 520
Background Systemic adjuvant treatment might mitigate the high risk of disease recurrence in patients with resected stage IIC-III melanoma. The BRIM8 study... 
HIGH-RISK MELANOMA | SURVIVAL | DABRAFENIB | THERAPY | METAANALYSIS | STAGE-III MELANOMA | HIGH-DOSE INTERFERON | ONCOLOGY | FOLLOW-UP | OPEN-LABEL | PEGYLATED INTERFERON-ALPHA-2B
Journal Article
ANNALS OF INTERNAL MEDICINE, ISSN 0003-4819, 03/2004, Volume 140, Issue 5, pp. 346 - 355
Background: Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in... 
ALPHA-2A | TRIAL | MEDICINE, GENERAL & INTERNAL | VIRUS | EFFICACY | PHARMACOKINETICS | SAFETY | INTERFERON-ALPHA-2B PLUS RIBAVIRIN | INITIAL TREATMENT | INFECTION | PEGYLATED INTERFERON-ALPHA-2B
Journal Article
NATURE COMMUNICATIONS, ISSN 2041-1723, 12/2014, Volume 5
Hepatitis C virus (HCV) infections are the major cause of chronic liver disease, cirrhosis and hepatocellular carcinoma worldwide. Both spontaneous and... 
IL28B | VIRUS | GENOTYPE | MULTIDISCIPLINARY SCIENCES | CHRONIC HEPATITIS-C | PEGYLATED INTERFERON | ALPHA | INFECTION | RIBAVIRIN THERAPY | VIRAL CLEARANCE | GENOME-WIDE ASSOCIATION
Journal Article
Nature Reviews Immunology, ISSN 1474-1733, 07/2015, Volume 15, Issue 7, pp. 405 - 414
Journal Article
Expert Opinion on Drug Metabolism & Toxicology, ISSN 1742-5255, 10/2019, Volume 15, Issue 10, pp. 779 - 785
Introduction: Interferon (IFN) had both antiviral and immunomodulatory effects, and was one of the approved treatments for hepatitis B virus (HBV). Herein, we... 
Pharmacodynamic | Interferon | Pegylated interferon | Pharmacokinetic | Mechanism
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2017, Volume 67, Issue 2, pp. 370 - 398
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2005, Volume 42, Issue 3, pp. 329 - 333
Interferon (IFN) monotherapy significantly reduces the chronicity rate of acute hepatitis C (AHC) but optimal regimen and treatment timing remain undefined.... 
Antiviral therapy | Hepatitis C virus | Pegylated interferon | Acute hepatitis C
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 522 - 530
Journal Article
Journal Article